The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Terns Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of novel therapies for liver and metabolic diseases. The company leverages a focused pipeline of ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, ...
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of ...
Terns Pharmaceuticals Inc.’s stock soared 17% Monday after the company said an early stage trial of its obesity treatment in pill form achieved statistically significant weight loss of up to 5.5% over ...
FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
(Reuters) -Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining drugmakers vying for a share of the lucrative weight-loss treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results